Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand and willingly sign a consent form before any study procedures begin
• People aged 18 to 75 years old at the time of signing the consent form
• People with a good general health and activity level, rated 0 or 1 on a standard cancer performance scale (meaning fully active or able to carry out light work)
• People with a life expectancy of at least 3 months
• People who have been formally diagnosed with extensive stage small cell lung cancer (a type of lung cancer that has spread), confirmed through a tissue or cell sample
• People who have not previously received systemic (whole-body) treatment for this cancer, OR people with extensive stage small cell lung cancer who previously received chemotherapy and radiation for an earlier, more limited stage of the disease, but whose cancer came back more than 6 months after that treatment ended
• People who have at least one measurable area of cancer that can be tracked using standard imaging assessment criteria
• People who are able to provide a stored tumour tissue sample (a specific type of preserved biopsy sample)
• People whose kidneys, liver, blood, and other organs are functioning adequately (confirm with trial site for specific thresholds)
• People of reproductive potential who agree to use an effective method of contraception during the study and for 120 days after the last dose of the study treatment

Who may not be able to join:

• People who have had another active cancer in the past 5 years, other than the cancer being studied in this trial or a previously cured localised cancer
• People who received certain local treatments or immune-modulating treatments within 2 weeks before the first dose, or certain Chinese herbal or traditional medicines with anti-cancer indications within 1 week before the first dose
• People who have previously received any treatment that targets the body's immune system to fight tumours
• People who have previously received any treatment designed to block the growth of blood vessels that feed tumours
• People whose tumour surrounds major blood vessels, shows significant breakdown or cavitation, or has grown into nearby important organs or blood vessels
• People who have had an active autoimmune disease requiring systemic treatment at any point in the 2 years before starting the study
• People who have cancer that has spread to the brain or spinal cord and is causing symptoms
• People with significant fluid build-up around the lungs, heart, or abdomen that requires frequent draining
• People who have had a hole or abnormal opening in the digestive tract, a bowel blockage requiring special nutrition, or major bowel surgery within 6 months before the first dose
• People with a known active Hepatitis B or Hepatitis C infection
• People who have had a heart attack, unstable chest pain, or heart or blood vessel surgery or procedures within 12 months before the study starts
• People who have had a serious infection within 4 weeks before the first dose, or who have been on systemic anti-infective treatment within 2 weeks before the first dose (not including hepatitis B or C antiviral therapy)
• People currently enrolled in another clinical trial that involves an active treatment, unless the last dose of that trial's treatment was more than 4 weeks ago or more than 5 half-lives of that drug ago (whichever is shorter)

Important: Always verify eligibility with the trial site directly before applying.